Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A STOLK

Showing results (81-90 of 167) with videos related to

Pageof 17
Sort By:
BMJ Global Health|August 13, 2021
Are current preventive chemotherapy strategies for controlling and eliminating neglected tropical diseases cost-effective?Hugo C Turner, Wilma A Stolk, Anthony W Solomon, et al.
Epidemics|March 11, 2017
Predicting lymphatic filariasis transmission and elimination dynamics using a multi-model ensemble frameworkMorgan E Smith, Brajendra K Singh, Michael A Irvine, et al.
Plos One|December 30, 2014
Elimination of African onchocerciasis: modeling the impact of increasing the frequency of ivermectin mass treatmentLuc E Coffeng, Wilma A Stolk, Achim Hoerauf, et al.
Biochimica Et Biophysica Acta|August 14, 1989
Interactions of Escherichia coli SO-187 tRNA(IVal) with Bacillus stearothermophilus valine-tRNA synthetase studied by 13C-NMRM P Schweizer, J I Olsen, J A Stolk, et al.
Current Medical Research and Opinion|January 21, 2016
Patient and physician preferences for oral pharmacotherapy for overactive bladder: two discrete choice experimentsM Heisen, S A Baeten, B G Verheggen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 22, 2016
Dutch Tariff for the Five-Level Version of EQ-5DMatthijs M Versteegh, Karin M Vermeulen, Silvia M A A Evers, et al.
Plos Neglected Tropical Diseases|January 10, 2013
Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasisWilma A Stolk, Quirine A ten Bosch, Sake J de Vlas, et al.
Infectious Diseases of Poverty|June 29, 2016
Progress towards onchocerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control: epidemiological evaluation resultsAfework H Tekle, Honorath G M Zouré, Mounkaila Noma, et al.
The Journal of Infectious Diseases|March 17, 2020
Structural Uncertainty in Onchocerciasis Transmission Models Influences the Estimation of Elimination Thresholds and Selection of Age Groups for SeromonitoringJonathan I D Hamley, Martin Walker, Luc E Coffeng, et al.
Parasitology|November 24, 2004
Meta-analysis of age-prevalence patterns in lymphatic filariasis: no decline in microfilaraemia prevalence in older age groups as predicted by models with acquired immunityW A Stolk, K D Ramaiah, G J Van Oortmarssen, et al.
Pageof 17

Showing results (81-90 of 167) with videos related to

Sort By:
Pageof 17
BMJ Global Health|August 13, 2021
Are current preventive chemotherapy strategies for controlling and eliminating neglected tropical diseases cost-effective?Hugo C Turner, Wilma A Stolk, Anthony W Solomon, et al.
Epidemics|March 11, 2017
Predicting lymphatic filariasis transmission and elimination dynamics using a multi-model ensemble frameworkMorgan E Smith, Brajendra K Singh, Michael A Irvine, et al.
Plos One|December 30, 2014
Elimination of African onchocerciasis: modeling the impact of increasing the frequency of ivermectin mass treatmentLuc E Coffeng, Wilma A Stolk, Achim Hoerauf, et al.
Biochimica Et Biophysica Acta|August 14, 1989
Interactions of Escherichia coli SO-187 tRNA(IVal) with Bacillus stearothermophilus valine-tRNA synthetase studied by 13C-NMRM P Schweizer, J I Olsen, J A Stolk, et al.
Current Medical Research and Opinion|January 21, 2016
Patient and physician preferences for oral pharmacotherapy for overactive bladder: two discrete choice experimentsM Heisen, S A Baeten, B G Verheggen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 22, 2016
Dutch Tariff for the Five-Level Version of EQ-5DMatthijs M Versteegh, Karin M Vermeulen, Silvia M A A Evers, et al.
Plos Neglected Tropical Diseases|January 10, 2013
Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasisWilma A Stolk, Quirine A ten Bosch, Sake J de Vlas, et al.
Infectious Diseases of Poverty|June 29, 2016
Progress towards onchocerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control: epidemiological evaluation resultsAfework H Tekle, Honorath G M Zouré, Mounkaila Noma, et al.
The Journal of Infectious Diseases|March 17, 2020
Structural Uncertainty in Onchocerciasis Transmission Models Influences the Estimation of Elimination Thresholds and Selection of Age Groups for SeromonitoringJonathan I D Hamley, Martin Walker, Luc E Coffeng, et al.
Parasitology|November 24, 2004
Meta-analysis of age-prevalence patterns in lymphatic filariasis: no decline in microfilaraemia prevalence in older age groups as predicted by models with acquired immunityW A Stolk, K D Ramaiah, G J Van Oortmarssen, et al.
Pageof 17